Merck & Co., Inc. $MRK Shares Sold by Castle Rock Wealth Management LLC

Key Points

• Castle Rock Wealth Management cut its Merck stake by 42.3% in the third quarter, selling 12,030 shares and retaining 16,389 shares valued at approximately $2.33 million. Institutional investors overall own 76.07% of MRK.
• Merck shares rose 2.2% to open at $145.52, supported by biotech-sector strength, FDA approval of the WELIREG-LENVIMA combination for advanced kidney cancer, and several analyst price-target increases. The stock carries a “Moderate Buy” consensus rating with an average target of $151.32.
• Key risks include a Dutch court ruling blocking Merck’s subcutaneous Keytruda formulation in eight European markets, upcoming patent losses and generic competition, and notable insider selling. Merck also pays a quarterly dividend of $0.85 per share, yielding about 2.3% annually.

Castle Rock Wealth Management LLC lessened its stake in Merck & Co., Inc. (NYSE:MRK - Free Report) by 42.3% in the 3rd quarter, according to its most recent filing with the SEC. The firm owned 16,389 shares of the company's stock after selling 12,030 shares during the quarter. Castle Rock Wealth Management LLC's holdings in Merck & Co., Inc. were worth $2,326,000 as of its most recent filing with the SEC.

Other institutional investors also recently added to or reduced their stakes in the company. Riversedge Advisors LLC raised its position in shares of Merck & Co., Inc. by 13.8% during the 3rd quarter. Riversedge Advisors LLC now owns 7,830 shares of the company's stock worth $1,138,000 after acquiring an additional 950 shares in the last quarter. Wedmont Private Capital boosted its holdings in Merck & Co., Inc. by 39.4% in the third quarter. Wedmont Private Capital now owns 39,432 shares of the company's stock valued at $5,614,000 after purchasing an additional 11,142 shares in the last quarter. Journey Retirement Planning & Investment Management LLC increased its stake in Merck & Co., Inc. by 8.9% in the third quarter. Journey Retirement Planning & Investment Management LLC now owns 8,236 shares of the company's stock valued at $1,197,000 after purchasing an additional 671 shares during the last quarter. Inspirion Wealth Advisors LLC acquired a new position in shares of Merck & Co., Inc. in the 3rd quarter valued at $240,000. Finally, Eclectic Associates Inc. ADV acquired a new position in shares of Merck & Co., Inc. in the 3rd quarter valued at $301,000. Hedge funds and other institutional investors own 76.07% of the company's stock.

Key Headlines Impacting Merck & Co., Inc.

Here are the key news stories impacting Merck & Co., Inc. this week:

• Positive Sentiment: Merck is participating in a broad rally across biotechnology and vaccine stocks, providing sector-wide momentum for MRK shares. Novavax Soars, Moderna Surges, Merck Climbs as Biotech Rallies
• Positive Sentiment: The FDA approved Merck’s WELIREG plus LENVIMA combination for adults with advanced kidney cancer previously treated with PD-1 or PD-L1 therapies. The approval expands Merck’s oncology opportunity beyond its core Keytruda franchise. Merck also started a Phase I trial involving Cyprumed’s oral peptide-delivery platform, adding a potential pipeline catalyst. Merck Wins FDA Approval for WELIREG Plus LENVIMA in Kidney Cancer
• Positive Sentiment: Cantor Fitzgerald raised its Merck price target to $145 from $120, while Morgan Stanley maintained or issued a Buy view in separate coverage. These actions suggest some analysts see the recent weakness and long-term growth prospects as attractive. Cantor Fitzgerald Lifts Price Targets on Four Pharma Giants
• Neutral Sentiment: Apella Capital increased its Merck position by 16.6% to 43,902 shares. The purchase indicates institutional confidence, although the position is too small to materially affect Merck’s fundamentals. Apella Capital Increases Stake in Merck
• Negative Sentiment: A Dutch court blocked Merck’s planned subcutaneous Keytruda product in eight European markets amid a patent dispute with Halozyme. The ruling could delay a potentially important reformulation and complicate efforts to extend Keytruda’s commercial life. HALO Wins Court Order Blocking Merck’s Keytruda SC in Europe
• Negative Sentiment: Merck is viewed as one of the pharmaceutical companies most exposed to upcoming patent losses and generic competition, raising longer-term concerns about revenue after Keytruda’s exclusivity period. Analysts have also flagged mixed growth prospects, while Morgan Stanley issued a separate pessimistic forecast. Pharma’s $500 Billion Patent Problem Will Come in Waves

Merck & Co., Inc. Trading Up 2.2%

Shares of Merck & Co., Inc. stock opened at $145.52 on Friday. The company has a 50-day moving average of $143.90 and a two-hundred day moving average of $128.28. Merck & Co., Inc. has a 12-month low of $82.01 and a 12-month high of $156.92. The company has a current ratio of 1.32, a quick ratio of 1.10 and a debt-to-equity ratio of 1.22. The stock has a market cap of $359.03 billion, a PE ratio of 116.42, a price-to-earnings-growth ratio of 6.41 and a beta of 0.21.

Merck & Co., Inc. (NYSE:MRK - Get Free Report) last announced its quarterly earnings results on Tuesday, August 4th. The company reported ($0.13) EPS for the quarter, topping the consensus estimate of ($0.26) by $0.13. Merck & Co., Inc. had a return on equity of 16.73% and a net margin of 4.77%. The business had revenue of $16.61 billion for the quarter, compared to analyst estimates of $16.37 billion. During the same quarter in the previous year, the company earned $2.13 EPS. The company's quarterly revenue was up 5.1% on a year-over-year basis. Merck & Co., Inc. has set its FY 2026 guidance at 2.660-2.760 EPS. On average, research analysts anticipate that Merck & Co., Inc. will post 2.67 EPS for the current fiscal year.

Merck & Co., Inc. Announces Dividend

The company also recently declared a quarterly dividend, which was paid on Wednesday, October 7th. Stockholders of record on Tuesday, September 15th were paid a dividend of $0.85 per share. This represents a $3.40 annualized dividend and a dividend yield of 2.3%. The ex-dividend date of this dividend was Tuesday, September 15th. Merck & Co., Inc.'s payout ratio is 272.00%.

Analyst Ratings Changes

Several brokerages have issued reports on MRK. Wolfe Research raised their price objective on Merck & Co., Inc. from $155.00 to $180.00 and gave the stock an "outperform" rating in a report on Tuesday, August 25th. Scotiabank boosted their target price on Merck & Co., Inc. from $155.00 to $180.00 and gave the company a "sector outperform" rating in a report on Tuesday, September 29th. Cantor Fitzgerald upped their target price on Merck & Co., Inc. from $120.00 to $145.00 and gave the company a "neutral" rating in a research report on Thursday. JPMorgan Chase & Co. raised their price target on Merck & Co., Inc. from $150.00 to $165.00 and gave the stock an "overweight" rating in a research note on Monday, October 5th. Finally, Wall Street Zen lowered Merck & Co., Inc. from a "buy" rating to a "hold" rating in a research report on Saturday, October 3rd. Seventeen analysts have rated the stock with a Buy rating and ten have issued a Hold rating to the company's stock. According to MarketBeat, the stock currently has an average rating of "Moderate Buy" and an average target price of $151.32.

Insiders Place Their Bets

In other news, EVP Richard Deluca sold 11,699 shares of the firm's stock in a transaction that occurred on Wednesday, August 12th. The shares were sold at an average price of $131.63, for a total transaction of $1,539,939.37. Following the completion of the transaction, the executive vice president directly owned 110,167 shares of the company's stock, valued at $14,501,282.21. This trade represents a 9.60% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, EVP David Maraldo sold 18,706 shares of the company's stock in a transaction that occurred on Wednesday, August 5th. The shares were sold at an average price of $128.72, for a total value of $2,407,836.32. Following the completion of the sale, the executive vice president directly owned 18,212 shares in the company, valued at approximately $2,344,248.64. The trade was a 50.67% decrease in their position. The SEC filing for this sale provides additional information. Over the last ninety days, insiders sold 228,238 shares of company stock valued at $29,977,783. Corporate insiders own 0.17% of the company's stock.

Merck & Co., Inc. Company Profile

Merck & Co, Inc is a global healthcare company that develops and markets prescription medicines, vaccines, and animal-health products. The company serves patients, healthcare providers, and customers in markets around the world, with research and commercial operations spanning multiple geographic regions.

Its pharmaceutical portfolio includes oncology, infectious-disease, cardiovascular, immunology, and other therapeutic areas. Key products include Keytruda, an oncology treatment; Gardasil, a human papillomavirus (HPV) vaccine; Januvia and Janumet for type 2 diabetes; Bridion for anesthesia-related use; and Winrevair for pulmonary arterial hypertension.

Want to see what other hedge funds are holding MRK? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Merck & Co., Inc. (NYSE:MRK - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.